Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-10-22
2009-11-03
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C424S278100
Reexamination Certificate
active
07611712
ABSTRACT:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RiNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
REFERENCES:
patent: 5443828 (1995-08-01), Kang et al.
patent: 5576421 (1996-11-01), Saito et al.
patent: 5817512 (1998-10-01), Morrow et al.
patent: 6627197 (2003-09-01), Keener
patent: WO 01/24810 (2001-04-01), None
patent: WO 2004002415 (2004-01-01), None
Mata, M., et al., 2001, “Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge”, Vaccine 19:1435-1445.
Flexner, C., et al., 1988, “Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses”, Virol. 166(2):339-349.
Azadegan, A. A., et al., 1984, “Cobra venom factor abrogates passive humoral resistance to syphilitic infection in hamsters”, Infect. Immun. 44(3):740-742.
HIV Immunology Epitope Search, Los Alamos Database, 2006.
Mata, M., et al., 2001, Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge, Vaccine 19:1435-1445.
Gowda, D. C., et al., 1994, Immunoreactivity and function of oligosaccharides in Cobra Venom Factor, J. Immunol. 152:2977-2986.
Frankel, F. R., et al., 1995, Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector, J. Immunol. 155:4775-4782.
Miller, M. A., et al., 1996, Protective immunity to Listeria monocytogenes elicited by immunization with heat-killed Listeria and IL-12, Annals N.Y. Acad. Sci. 797:207-227 (abstract provided).
Human Retroviruses and AIDS 1999: A compilation and analysis of nucleic acid and amino acid sequences. Kuiken, C. L., et al., eds., Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, HIV/SIV Gag sequence compendium, pp. 332-341.
Aiken, C. et al., “Inside-out Regulation of HIV-1 Particle Fusion,” Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA USA Abstract 17 (Feb. 10-14, 2003).
Aroeti, Benjamin, et al., Mutational and Secondary Structural Analysis of the Basolateral Sorting Signal of the Polymeric Immunoglobulin Receptor, J. Cell Biology, vol. 123, No. 5, 1149-1160 (1993).
Ara, Yuki, et al., “Zymozan enhances the immune response to DNA vaccine for human immunodeficiency virus type-I through the activation of complement system” Immunology 103: 98-105 (2001), Japan.
Aslam, Mohammed, et al., “Folded Back Solution Structure of Monomeric Factor H of Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Modelling,” Molecular Biology, vol. 309, pp. 1117-1138 (2001).
Ault, Bettina, et al., “Human Factor H Deficiency,” Biological Chemistry, vol. 272, #40, pp. 25168-25175 (1997), USA.
Blackmore, T. K., et al., “Identification of a Heparin Binding Domain in the Seventh Short Consensus Repeat of Complement Factor H,” Immunology, vol. 157, Iss 12, pp. 5422-5427 (1996).
Braaten, D., et al., “Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting of human T Cells,” The EMBO Journal, vol. 20, No. 6, pp. 1300-1309, 2001.
Brooks, Geo. F., Medical Microbiology Ch. 3 & 7 (23rd Ed. 2004).
Burger, R., et al., “Activation of the alternative pathway of complement: efficient fluid-phase amplification by blockade of the regulatory complement protein B1H through sulfated polyanions,” European J. Immunology, vol. 11, pp. 291-295 (1981).
Doepper, Susi, et al, “Complement Receptors in HIV Infection,” Current Molecular Medicine, vol, 2, Iss 8, pp. 703-711 (2002).
Burger, R., et al., “Dextran Sulphate: a Synthetic Activator of C3 via the Alternative Pathway,” Immunology, vol. 29. pp. 549-554 (1975).
Burger, R., et al., “Insoluble polyanions as activators of both pathways of complement,” Immunology 33:827-837 (1977).
Chan, D. C., et al., “Core Structure of gp41 from the HIV Envelope Glycoprotein” Cell, vol. 89, Issue 2, pp. 263-273 (Apr. 18, 1997).
Chen, Chien-Hung, et al., “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene,” Cancer Research 60:1035-1042 (Feb. 15, 2000).
Cheng, Wen-Fang, et al., “Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen,” Journal of Clinical Investigation, vol. 108, No. 5, 669-678 (Sep. 2001).
Hung, Chien-Fu, et al., “Enhancing Major Histocompatibility Complex Class I Antigen Presentation by Targeting Antigen to Centrosornes,” Cancer Research 63: 2393-2398 (May 15, 2003).
Cohen, P.T., The AIDS Knowledge Base, 15-18, 21 (3rd ed. 1999).
Cummings, Melissa, et al., New Research Uncovers Potential for More Effective Anti-HIV Therapies: Essential Role of Cyclophilin, Novel Non-Mutable Drug Target Discovered, PR NewsWire 1996.
Dierich, M. P., et al., “HIV and human complement: mechanisms of interaction and biological implication,” Immunology Today, vol. 14, Iss 9, pp. 435-440 (1993).
Discipio, R. G., “Ultrastructures and interactions of complement factors H and I,” J. Immunology, vol. 149, Iss 8, pp. 2592-2599 (1992).
Fearon, D.T., et al., “Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms,” Proc. Natl. Acad. Sci, vol. 74, No. 4, pp. 1683-1687 (Apr. 1977).
Feifel, Elisabeth, et al., “Polymorphism and deficiency of human factor H-related proteins p39 and p37,” Immunogenetics, vol. 36, pp. 104-109 (1992).
Fishelson, Z., et al., “C3 Convertase of Human Complement: Enhanced Formation and Stability of the Enzyme Generated with Nickel instead of Magnesium,” J. of lmmun., vol. 129, No. 6, pp. 2603-2607 (Dec. 1982).
Forrest, Bruce D., et al., “Effect of Parenteral Immunization on the Intestinal Immune Response to Salmonella typhy Ty21a,” Infection and Immunity, vol. 60, No. 2, pp. 465-471 (Feb. 1992).
Franke, E. K., et al., “Chaperoning a pathogen,” Nature, 372 (6504): 319-20 (Nov. 24, 1994).
Franke, E. K., et al., “Specific Incorporation of Cyclophilin A Into HIV-1 Virions,” Nature, 372(6504): 359 (Nov. 24, 1994).
Friese, M. A., “FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated,” Molecular Immunology, vol. 36, pp. 809-818 (1999).
Furie, Bruce, “Oral Anticoagulant Therapy,” Hematology Basic Principles & Practice, Ch. 121. pp. 2040-2046 (3rd ed. 2000).
Gardner, William D., “Identification of a major human serum DNA-binding protein as B1H of the alternative pathway of complement activation,” Biochemical and Biophysical Research Communications, vol. 94, pp. 61-67 (1980).
Gasque, P., “Expression of complement components of the alternative pathway by glioma cell lines,” Immunology, 149:1381-87 (1992).
Giannakis, Eleni, et al., “Multiple ligand binding sites on domain seven of human complement factor H,” Int'l Immunopharmacology, vol. 1, Issue 3, pp. 433-443 (2001).
Goudsmit, J., Immunodominant B-Cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts, AIDS, vol. 2 (Suppl I): S41-S45 (1988).
Gowda, D. C., et al., “Immunoreactivity and Function of Oligosaccharides in Cobra Venom
Karp Nelson M.
Parkin Jeffrey
Williams Mullen
LandOfFree
Immunogenic compositions capable of eliciting Th1 immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic compositions capable of eliciting Th1 immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic compositions capable of eliciting Th1 immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058737